Russians have spent over 8.68 billion rubles on acne medications at retail prices, a 51% increase y-o-y. In natural units, sales amounted to almost 5.89 million packages, an increase of 28.5%. According to the analytical company RNC Pharma, the market continued to grow for the third consecutive year in January–June 2025, demonstrating double-digit growth: by the end of 2024, 9.88 million packages were sold—up 24.9%—valued at 12.94 billion rubles, an increase of 48.3%.
Demand traditionally peaked in the spring months. In March 2025, an all-time record was achieved: over 1 million packages worth 1.49 billion rubles were sold, representing increases of 50.8% in value and 27.5% in volume compared to March 2024. The average package price in the first half of the year was approximately 1,500 rubles, with an inflation rate not exceeding 8%.
In monetary terms, oral medications account for 55% of the market, with 70.7% of packaged sales originating from local products. Retinoids, especially isotretinoin, occupy the largest share in this category of 13 INNs. Drugs containing this active ingredient accounted for 55% of sales in cash (4.8 billion rubles) and 31% in packages.
The Croatian drug Acnecutan (Jadran) remains the market leader with a share of 31.86% in monetary terms and 16.37% in packages, followed by Indian Sotret (Sun Pharmaceutical) with 17.63%. Both products are capsules with isotretinoin. The third position is occupied by the Swiss gel Effezel (Galderma) based on adapalene and benzoyl peroxide.
Almost all of the top 10 drugs, except for the original Roaccutane (Roche), experienced double-digit growth: sales of Acnecutane increased by 84%, while Clinzol ZD gel (Zelenaya Dubrava) grew 4.5 times. In contrast, Roaccutane’s sales fell by 7% in ruble terms and by 14% in packages.
